KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Sales (2020 - 2025)

Recursion Pharmaceuticals' Return on Sales history spans 6 years, with the latest figure at 3.04% for Q4 2025.

  • For Q4 2025, Return on Sales rose 3631.0% year-over-year to 3.04%; the TTM value through Dec 2025 reached 8.63%, down 75.0%, while the annual FY2025 figure was 8.63%, 75.0% down from the prior year.
  • Return on Sales reached 3.04% in Q4 2025 per RXRX's latest filing, up from 31.35% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.04% in Q4 2025 to a low of 39.35% in Q4 2024.
  • Average Return on Sales over 5 years is 12.17%, with a median of 8.73% recorded in 2022.
  • Peak YoY movement for Return on Sales: surged 29382bps in 2021, then crashed -3082bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 25.65% in 2021, then skyrocketed by 83bps to 4.46% in 2022, then crashed by -91bps to 8.54% in 2023, then crashed by -361bps to 39.35% in 2024, then soared by 92bps to 3.04% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Return on Sales are 3.04% (Q4 2025), 31.35% (Q3 2025), and 8.94% (Q2 2025).